Farber disease: clinical presentation, pathogenesis and a new approach to treatment
© Ehlert et al; licensee BioMed Central Ltd. 2007
Received: 19 February 2007
Accepted: 29 June 2007
Published: 29 June 2007
Farber Disease is an autosomal-recessively inherited, lysosomal storage disorder caused by acid ceramidase deficiency and associated with distinct clinical phenotypes. Children with significant neurological involvement usually die early in infancy, whereas patients without or only mild neurological findings suffer from progressive joint deformation and contractures, subcutaneous nodules, inflammatory, periarticular granulomas, a hoarse voice and finally respiratory insufficiency caused by granuloma formation in the respiratory tract and interstitial pneumonitis leading to death in the third or fourth decade of live. As the inflammatory component of this disorder is caused by some kind of leukocyte dysregulation, allogeneic hematopoietic stem cell transplantation can restore a healthy immune system and thus may provide a curative option in Farber Disease patients without neurological involvement. Previous stem cell transplantations in two children with severe neurological involvement had resulted in a disappointing outcome, as both patients died of progressive deterioration of their neurological status. As a consequence, stem cell transplantation does not appear to be able to abolish or even reduce the neurotoxic effects of the abundant ceramide storage in the brain.
After myeloablative, busulfan-based preparative regimens, four Farber Disease patients without neurological involvement received an allogeneic hematopoietic stem cell transplantation from related and unrelated donors. Stem cell source was BM in three patients and PBSC in one patient; GvHD-prophylaxis consisted of CsA and short course MTX.
Results and discussion
In all patients, HSCT resulted in almost complete resolution of granulomas and joint contractures, considerable improvement of mobility and joint motility without relevant therapy-related morbidities. All patients are alive and well at this point with stabile donor cell chimerism and without evidence of chronic GvHD or other late sequelae of stem cell transplantation.
Allogeneic hematopoietic stem cell transplantation provides a promising approach for Farber Disease patients without neurological involvement.
Part I: Clinical presentation of Farber Disease
Background: First description of Farber Disease
Ceramidase deficiency (Farber lipogranulomatosis or Farber Disease), first described as an inborn storage disease by Farber and coworkers [1, 2], leads to tissue accumulation of ceramide due to deficient activity of lysosomal ceramidase.
The clinical presentation of Farber Disease (FD) is characterized by the appearance of subcutaneous skin nodules, ordinarily near the joints, most often interphalangeal, wrist, elbow and ankle joints, or over points of mechanical pressure. These manifestations are very painful and lead to progressive joint stiffness, limitation of motion by contractures and finally to immobilization and deformation of joints. Also, a characteristic sign of FD is the development of a progressive hoarseness due to laryngeal involvement .
Beside these major manifestations seven phenotypes have been described which differ in severity and additional organ involvement, like the lungs, nervous system, heart and lymph nodes . Dependent on residual lysosomal ceramidase turnover, patients have a variable degree of central nervous system disease, leading to progressive neurologic deterioration. In most cases the neuronal dysfunction rather than the general physical dystrophy seems to limit the duration of FD . As well, patients with FD may die due to pulmonary disease with interstitial pneumonia.
First symptoms usually appear between the newborn period and the first birthday. Milder forms of type 3 were described with onset at 20 months of age. Clinical manifestation in type 5 of FD, dominated by neurologic deterioration, begins at 1 to 2 1/2 years of life. Patients mainly die within the first years of life, but prolonged courses in patients without severe CNS disease may also be observed .
Phenotypes of Farber Disease
Type 1 is the classic form of the disease with early subcutaneous nodules, joint involvement and hoarseness in all cases. Progressive neurologic involvement and lung disease are reported in many cases .
In contrast, type 2 and 3 patients show only slight or no symptoms of central nervous system disease. However, they still have a severe disease as a result of granulomatous inflammation leading to subcutaneous nodules, joint pain and contractures, hoarseness, failure to thrive and respiratory involvement .
Patients with type 4 FD present with severe neurologic deterioration and large hepatosplenomegaly already in the neonatal period. Histopathology shows massive granulomatous infiltrations by accumulating macrophages in liver, spleen, lymphoid tissue, thymus and lungs .
The major clinical presentation in type 5 patients is a progressive CNS dysfunction, beginning at 1 to 2 1/2 years of life and manifestating in tetraplegia, loss of speech, myoclonia, seizures and mental retardation .
Type 6 is a combination of type 1 FD and Sandhoff disease , another lysosomal storage disorder caused by hexosaminidase A and B enzyme defects. Both acid ceramidase and hexosaminidase A and B are involved in the catabolism of glycosphingolipids.
One patient is classified as type 7, showing a combined deficiency of glucocerebrosidase, galactocerebrosidase and ceramidase due to a mutation of prosaposin, the precursor protein for two sphingolipid activator proteins .
Diagnosis of Farber Disease
In typical cases of type 1 FD the clinical triad of subcutaneous nodules, joint and laryngeal involvement verifies the disease. When typical features are missing, diagnosis is confirmed by determination of acid ceramidase activity, which is less than 6 percent of control values, measured in cultured skin fibroblasts, white blood cells or amniocytes . Another diagnostic approach is the demonstration of typical histopathologic features on biopsy, showing granulomas with macrophages containing lipid cytoplasmic inclusions in subcutaneous nodules or other tissues . Determination of ceramide accumulation in tissues by chromatography or mass spectrometry is also an established diagnostic test for FD .
Part II: Etiology and pathogenesis of Farber Disease
The curative effect of HSCT on the inflammatory symptoms in FD indicates that the granulomatous inflammation in these patients is not a consequence of mere ceramide storage but reflects a dysregulation of leukocyte functions, probably due to the intracellular role of ceramide in intracellular signal transduction . However, the sequence of molecular mechanisms leading from a defect in ceramide metabolism to chronic granulomatous inflammation still needs elucidation. Alterations of receptor-mediated apoptosis by ceramide accumulation in inflammatory cells may be one of the mechanisms underlying abnormal granuloma formation.
Recent evidence suggests that the sphingolipid ceramide plays an important role as a second messenger in a number of signal transduction pathways. Many cellular responses to extracellular stimuli have been linked to the intracellular generation of ceramide, especially the induction of apoptotic cell death triggered by various stress agents. Ceramide has been proposed to mediate apoptosis, because many pro-apoptotic stimuli induce the production of ceramide and treatment with exogenously added ceramides can induce apoptotic cell death .
In a previous study we have shown that cells obtained from a FD patient showed remarkable changes in their sensitivity to different apoptotic stimuli . When treated with staurosporine, chemotherapeutic drugs or ionizing radiation, FD cells underwent apoptosis and activated caspases comparable to control cells. However, due to the lack of ceramidase, cell-permeable ceramides had a stronger pro-apoptotic activity in Farber cells than in controls. Interestingly, we consistently observed an accelerated rate of lymphocyte death in FD upon activation of the death receptor molecule fas (CD95). These data suggest that ceramide does not play an essential role as a general trigger or second messenger in all kinds of apoptosis, but may rather act as a specific amplifier of receptor-induced cell death . There is growing evidence that generation of ceramide increases membrane fluidity and raft formation in the plasma membrane, thereby facilitating receptor mediated signalling. Indeed, recent studies showed that ceramide may be critically involved in cap formation, clustering, and activation of the CD95 receptor [12, 13].
As a major symptom FD patients exhibit chronic destructive joint inflammation resembling rheumatoid arthritis. Indeed, increased CD95 receptor/ligand interaction has been implicated in the pathogenesis of inflammatory arthritis [10, 11]. It may therefore be speculated that increased CD95 signalling mediated by elevated ceramide levels is involved in the inflammatory arthritis of FD.
Part III: Therapeutic approaches to Farber disease patients without CNS involvement
For some decades now, allogeneic hematopoeitic stem cell transplantation has proven to provide a potential, curative approach to malignant  and non-malignant diseases. Additionally, it has also shown efficacy in some inherited disorders, predominantly primary immunodeficiencies and lysosomal storage disorders [19, 24]. Symptoms of disease in these metabolic disorders are usually caused by the lack of enzyme activity. The transplantation of hematopoetic stem cells from a healthy donor can be a source of a sufficient amount of enzyme and thus abolish or at least decrease or stabilize symptoms of disease in some patients [18, 20–22].
The etiology of Farber disease is the lack of acid ceramidase, and subsequently there is an increased storage of ceramide in several organs and tissues . However, as already illuminated in the previous two chapters of this article, the main symptoms of disease in these patients, at least in those without involvement of the central nervous system, are caused by some kind of leukocyte dysregulation . The dysfunction of the immune system results in the inflammatory component of the disorder with painful swelling of several joints, granuloma formation, contractures and inflammatory airway involvement. Current management for these patients has therefore focused on pain therapy, physcial therapy, surgical correction of severe contractures and anti-inflammatory medication. The affected patients usually die in the second decade of their lives as a consequence of granuloma formation in the respiratory tract and their immobility with recurrent episodes of pneumonia and resulting respiratory insufficiency .
Previous reports on allogeneic HSCT in Farber disease patients
The first reports on hematopoietic stem cell transplantion in two Farber disease patients were published in 1989 and 2000 by Souillet and Yeager [25, 26]. However, both children had a subtype of Farber disease with involvement of the central nervous system and died because of a deterioration of their neurological status. So, as is also the case in other lysosomal storage disorders with severe CNS disease , hematopoietic stem cell transplantation does not seem to provide a benefit for these children, as it is not able to abolish or even reduce the neurotoxic effects of excessive ceramide accumulation in the brain. However, as HSCT can provide a healthy immune system and thus correct the abnormal inflammatory response and symptoms of disease, there could be an option for hematopoietic stem cell transplantation in those children with a predominance of the inflammatory component of the disorder. Additionally, resolution of granulomas after hematopoietic stem cell transplantation could also be demonstrated in children with central nervous system involvement [25, 26].
Present experience of allogeneic HSCT in Farber disease patients without CNS involvement
Transplant-related data of patients
Patient number and gender
Age at SCT
Stem cell source and dose (no T-cell depletion)
BM (MRD), 11.3 × 106 CD34
PBSC (MUD), 25 × 106 CD34
BM (MRD), 5.6 × 106 CD34
BM (MRD), 4.2 × 106 CD34
grade II of gut/none
grade I of gut/none
grade II of skin/none
Therapy of acute/chronic GvHD
steroids + tacrolimus/none
Clostridium difficile enteritis, bacteremia with Staphylococci
Current donor cell chimerism
The preparative regimen, consisting of intravenous (patients #1 to #3) or oral busulfan (patient #4) and cyclophosphamide, was tolerated well; no neurological, renal, skin or lung toxicities were observed. In patients #1, #3 and #4 bone marrow was the stem cell source, in patient #2 peripheral blood stem cells were used; no in-vitro-T cell depletion was performed. GvHD prophylaxis consisted of ciclosporine and short course methotrexate. Engraftment was noted between days +12 and +18. Patients #1, #2 and #3 developed mild acute GvHD, but no evidence of chronic GvHD so far. Therapy for acute GvHD consisted of steroids in all affected patients, and in patient #3, of additional tacrolimus instead of ciclosporine, as she experienced ciclosporine-induced-neurotoxicity. Transplant related morbidity in our patients was moderate. CMV-reactivation and -colitis in patients #2 and #3, respectively, was controlled by intravenous ganciclovir. For treatment of Clostridium difficile enteritis and Staphylococci bacteremia, patient #1 was given oral vancomycin and iv teicoplanin. On routine ophthalmological examination on day +100, patient #1 was diagnosed with papillary edema, most probably due to elevated intracranial pressure as a consequence of medication with ciclosporine; she was switched to tacrolimus, although she did not suffer from clinical neurotoxicity. In contrast, clinical signs of neurotoxicity by ciclosporine were observed in patient #3; she presented with a generalized seizure, stroke-like symptoms and the characteristic findings in MR imaging studies. Both patients #1 and #3 were switched from ciclosporine to tacrolimus without further difficulties. Hemiparesis in patient #3 gradually resolved within a few months.
In contrast to the natural course of disease in Farber patients, which is characterized by progressive joint deformation, immobility, pain and finally restriction to wheel-chairs, all of the transplanted patients demonstrated a gradual improvement in mobility, reduced number of joints with restricted motion, less pain and significant gain of function. Prior to her transplant, patient #1 was almost wheel-chair bound and could hardly walk, as she suffered from severe contractures in numerous joints. Figures 1 to 3 clearly illustrate the substantial benefit of HSCT in this patient, as shown with the pre- and post-transplant status of her hands.
Post-transplant follow-up of patients
Patient number and gender
Time point of follow-up
prior to SCT
prior to SCT
prior to SCT
prior to SCT
ESR (mm, first hour, Westergren)
no data available
Time point of follow-up
prior to SCT
prior to SCT
prior to SCT
prior to SCT
Number of nodules
pre Tx-nodules mainly dissolved, no new nodules
Number of joints with restricted mobility
almost all joints affected, however considerable improvement after HSCT
It is clearly evident that the present experience with hematopoietic stem cell transplantation in Farber Disease is still limited. HSCT may not be appropriate for patients with CNS involvement as ceramide neurotoxicity may not be reversible by stem cell transplantation. After a myeloablative, busulfan-based preparative regimen, a rapid engraftment was demonstrated with only moderate acute GvHD, no signs of chronic GvHD and low therapy-related morbidity. Donor cell chimerism is between 90 and 100% which seems to be sufficient for important reduction of disease-specific symptoms as all transplanted patients had a considerable improvement in joint mobility and a decreasing number of granulomas.
In conclusion, despite the preliminary nature of the data on hematopoietic stem cell transplantation in Farber Disease without central nervous system involvement, we have demonstrated a promising therapeutic approach for these patients.
cluster of differentiation
central nervous system
C reactive protein
erythrocyte sedimentation rate
hematopoietic stem cell transplantation
matched related donor
matched unrelated donor
peripheral blood stem cells
stem cell transplantation
- Farber S: A lipid metabolic disorder: disseminated lipogranulomatosis: a syndrome with similarity to, and important difference from, Niemann-Pick and Hand-Schüller-Christian disease. American Journal of Diseases in Childhood. 1952, 84 (4): 499-500.Google Scholar
- Farber S, Cohen J, Uzman LL: Lipogranulomatosis: a new lipo-glycoprotein storage disease. Journal of Mt Sinai Hospital N Y. 1957, 24 (6): 816-837.Google Scholar
- Levade T, Moser HW, Fensom AH, Harzer K, Moser AB, Salavayre R: Neurodegenerative course in ceramidase deficiency (Farber disease) correlates with the residual lysosomal ceramide turnover in cultured living patient cells. Journal of Neurological Sciences. 1995, 134 (1-2): 108-114. 10.1016/0022-510X(95)00231-0.View ArticleGoogle Scholar
- Moser HW, Linke T, Fensom AH, Levade T, Sandhoff K: Acid ceramidase deficiency: Farber lipogranulomatosis. The Metabolic and Molecular Bases of Inherited Disease. Edited by: Scriver CR. 2001, New York: McGraw-Hill, 3573-3585. 8Google Scholar
- Pavone L, Moser HW, Mollica F, Reitano C, Durand P: Farber's lipogranulomatosis: Ceramidase deficiency and prolonged survival in three relatives. Johns Hopkins Medical Journal. 1980, 147: 193-196.PubMedGoogle Scholar
- Antonarakis SE, Valle D, Moser HW, Kishimoto Y: Phenotypic variability in siblings with Farber disease. Journal of Pediatrics. 1984, 104: 406-409.View ArticlePubMedGoogle Scholar
- Eviatar L, Sklower SL, Wisniewski K, Feldman RS, Gochoco A: Farber (lipogranulomatosis): An unusual presentation in a black child. Pediatric Neurology. 1986, 2: 371-374. 10.1016/0887-8994(86)90082-2.View ArticlePubMedGoogle Scholar
- Fusch C, Huenges R, Moser HW, Sewell AC, Roggendorf W, Kusterman K, Harzer K: A case combined Farber's and Sandhoff's disease. European Journal of Pediatrics. 1989, 148: 558-562. 10.1007/BF00441558.View ArticlePubMedGoogle Scholar
- Schnabel D, Schröder M, Furst W, Klein A, Hurwitz R, Zenk T, Weber J, Harzer K, Paton BC, Poulos A, Suzuki K, Sandhoff K: Simultaneous deficiency of sphingolipid activator proteins 1 and 2 is caused by a mutation in the initiation codon of their common gene. Journal of Biochemical Chemistry. 1992, 267 (5): 3312-3315.Google Scholar
- Hoang TR, Hammermuller A, Mix E, Kreutzer HJ, Goerlich R, Kohler H, Nizze H, Thiesen HJ, Ibrahim SM: A proinflammatory role for Fas in joints of mice with collagen-induced arthritis. Arthritis Research and Therapy. 2004, 6 (5): R404-414. 10.1186/ar1205.View ArticleGoogle Scholar
- Ma Y, Liu H, Tu-Rapp H, Thiesen HJ, Ibrahim SM, Cole SM, Pope RM: Fas ligation on macrophages enhances IL-1R1-Toll-like receptor 4 signalling and promotes chronic inflammation. Nature Immunology. 2004, 5 (4): 380-387. 10.1038/ni1054.View ArticlePubMedGoogle Scholar
- Grassme H, Jekle A, Riehle A, Schwarz H, Berger J, Sandhoff K, Kolesnick R, Gulbins E: CD95 signalling via ceramide-rich membrane rafts. Journal of Biological Chemistry. 2001, 276 (23): 20589-20596. 10.1074/jbc.M101207200.View ArticlePubMedGoogle Scholar
- Cremesti A, Paris F, Grassme H, Holler N, Tschopp J, Fuks Z, Gulbins E, Kolesnick R: Ceramide enables fas to cap and kill. Journal of Biological Chemistry. 2001, 276 (26): 23954-23961. 10.1074/jbc.M101866200.View ArticlePubMedGoogle Scholar
- Levade T, Jaffrezou JP: Signalling sphingomyelinases: which, where, how and why?. Biochemical and Biophysical Acta. 1999, 1438 (1): 1-17.View ArticleGoogle Scholar
- Burek C, Roth J, Koch HG, Harzer K, Los M, Schulze-Osthoff K: The role of ceramide in receptor- and stress-induced apoptosis studied in acidic ceramidase-deficient Farber disease cells. Oncogene. 2001, 20 (45): 6493-6502. 10.1038/sj.onc.1204841.View ArticlePubMedGoogle Scholar
- Mathias S, Pena LA, Kolesnick RN: Signal transduction of stress via ceramide. Biochemical Journal. 1998, 335: 465-480.PubMed CentralView ArticlePubMedGoogle Scholar
- Sanders JE: Bone marrow transplantation for pediatric malignancies. Pediatric clinics of North America. 1997, 44 (4): 1005-1020. 10.1016/S0031-3955(05)70542-3.View ArticlePubMedGoogle Scholar
- Vormoor J, Marquardt T: Hematopoietic cell transplantation in inborn errors of metabolism. Current opinion in organ transplantation. 2004, 9: 43-48. 10.1097/00075200-200403000-00010.View ArticleGoogle Scholar
- Malatack JJ, Consolini DM, Bayever E: The status of hematopoietic stem cell transplantation in lysosomal storage disease. Pediatric Neurology. 2003, 29 (5): 391-403. 10.1016/j.pediatrneurol.2003.09.003.View ArticlePubMedGoogle Scholar
- Wilcox WR: Lysosomal storage disorders: The need for better pediatric recognition and comprehensive care. The Journal of Pediatrics. 2004, 144: S3-S14. 10.1016/j.jpeds.2004.01.049.View ArticlePubMedGoogle Scholar
- Schiffmann R, Brady RO: New prospects for the treatment of lysosomal storage diseases. Drugs. 2002, 62 (5): 733-742. 10.2165/00003495-200262050-00002.View ArticlePubMedGoogle Scholar
- Peters C, Steward CG: Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines. Bone marrow transplantation. 2003, 31: 229-239. 10.1038/sj.bmt.1703839.View ArticlePubMedGoogle Scholar
- Baumann M, Korenke GC, Weddige-Diedrichs A, Wilichowski E, Hunneman DH, Wilken B, Brockmann K, Klingebiel T, Niethammer D, Kuehl J, Ebell W, Hanefeld F: Haematopoietic stem cell transplantation in 12 patients with cerebral X-linked adrenoleukodystrophy. European Journal of Pediatrics. 2003, 162: 6-14. 10.1007/s00431-002-1097-3.View ArticlePubMedGoogle Scholar
- Buckley RH: A historical review of bone marrow transplantation for immunodeficiencies. Journal of allergy and clinical immunology. 2004, 113 (4): 793-800. 10.1016/j.jaci.2004.01.764.View ArticlePubMedGoogle Scholar
- Souillet G, Guibaud P, Fensom AH, Maire I, Zabot MT: Outcome of displacement bone marrow transplantation in Farber's disease: a report of a case. Correction of certain genetic diseases by transplantation. Edited by: Hobbs JR. 1989, London: COGENT, 137-141.Google Scholar
- Yeager AM, Armfield-Uhas K, Coles CD, Davis PC, Krause WL, Moser HW: Bone marrow transplantation for infantile ceramidase deficiency (Farber disease). Bone marrow transplantation. 2000, 26: 357-363. 10.1038/sj.bmt.1702489.View ArticlePubMedGoogle Scholar
- Vormoor J, Ehlert K, Groll AH, Koch HG, Frosch M, Roth J: Successful hematopoietic stem cell transplantation in Farber disease. The Journal of Pediatrics. 2004, 144 (1): 132-134. 10.1016/j.jpeds.2003.09.051.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.